ArticleAnnals of surgical oncology2026
Prefoldin Subunit 2 Promotes Migration of Hepatocellular Carcinoma Cells and Is Associated with Poor Prognosis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPrefoldin subunit 2 (PFDN2), a component of the prefoldin complex, has been implicated in tumor progression and in cytoskeleton-related progression; however, its clinical relevance and biological role in hepatocellular carcinoma (HCC) remain unclear. This study investigated the clinicopathological relevance and functional role of PFDN2 in HCC. MATERIALS AND
methodsProtein expression of prefoldin subunits (PFDN1-6) was examined in 265 HCC specimens using tissue microarrays. Associations with clinicopathological features and survival outcomes were analyzed. Functional roles of PFDN2 were assessed using Huh7 cells overexpressing PFDN2 (PFDN2-OE) and HLF cells with PFDN2 knockdown (PFDN2-KD). Migration, invasion, and proliferation assays were conducted, along with western blot analyses of Rac1-associated signaling and endoplasmic reticulum (ER) stress markers.
resultsElevated PFDN2 expression was significantly associated with poor tumor differentiation and vascular invasion. Patients with high PFDN2 expression had worse overall and recurrence-free survival (p = 0.0257 and p = 0.0255, respectively). In vitro, PFDN2-OE enhanced migratory capacity and lamellipodia formation, accompanied by upregulation of Rac1, phosphorylated Rac1, Tiam1, and ARHGAP1. PFDN2-KD suppressed proliferation and increased ER stress markers, including PERK, phosphorylated PERK, and CHOP.
conclusionsPFDN2 overexpression is associated with aggressive tumor features and poor prognosis in HCC. PFDN2 promotes migratory activity through Rac1-associated signaling and may support cellular proliferation. These findings suggest that PFDN2 may serve as a molecular indicator of aggressive tumor behavior and potentially contribute to postoperative risk stratification.
Indexed as
Identifiers
42881352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.